Fig. 4: Response to chemotherapy in advanced cases.
From: The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer
a Waterfall plot comparing response to platinum for advanced (stage III and IV) patients in the COMPASS/PanCuRx cohort on the left and for response to platinum for moffitt classic patients in the COMPASS/PanCuRx cohort on the right. b Kaplan-Meier curves for all advanced (Stage III/IV) patients, those receiving platinum based chemotherapy and Moffit classical cases that received platinum based therapy. c Kaplan-Meier curves of advanced patients receiving platinum based chemotherapies. (ii) Boxplot of chemotherapy duration across the etiologies. d Kaplan-Meier curves of advanced patients (Stage III/IV) receiving platinum-based chemotherapy by group 1 vs. group 2 TDP. BRCA1 samples are included in the HRD group while CCNE1 samples are in group 2.
